14 results about "Genomic rna" patented technology

This invention discloses a quantitative genomic RNA standard for the BCR-ABL1 fusion gene and its preparation method. The method involves extracting genomic RNA containing two mutant forms of the BCR-ABL1P210 fusion gene, b2a2 and b3a2. RNA storage buffer and quantitative standard solutions are prepared, and corresponding primers and probes are designed. A one-step reverse transcription digital PCR method is used, with the BCR-ABL1P210 fusion mutant genomic RNA as a template for PCR amplification. Fluorescence signals are collected to detect the expression of the BCR-ABL1P210 fusion genes b2a2 and b3a2, thereby obtaining the copy number content of the BCR-ABL1P210 fusion genes b2a2 and b3a2 and the abundance of the mutant gene in ABL-WT as quantitative values.

The invention discloses application of neochlorogenic acid in preparation of a medicine for preventing and / or treating hand-foot-and-mouth disease caused by A16 type coxsackie virus (CVA16) infection, and belongs to the technical field of biological medicine. Researches prove that the neochlorogenic acid has the effect of resisting CVA16 infection on HEK293T cells and H4 cells, after the two cells treated by the neochlorogenic acid are infected by the CVA16, the viral genome RNA abundance is obviously reduced, and the cell lesion death condition is obviously relieved; meanwhile, a cytotoxicity test shows that the neochlorogenic acid has no obvious cytotoxicity to HEK293T cells and only has weak cytotoxicity to H4 cells. Therefore, in a reasonable dosage range, the neochlorogenic acid, which is a low-toxicity natural small molecule compound, can be used for preparing the anti-CVA16 medicine for preventing and / or treating the hand-foot-and-mouth disease caused by CVA16 infection.

A method of detecting severe disease-associated mutations in an enterovirus 71 (EV-A71), comprising: performing an assay on a test sample containing an EV-A71 genomic RNA, a fragment thereof or an amplicon thereof, or an EV-A71 VP1 protein or fragment thereof to detect one or more severe disease-associated mutations in the EV-A71 genomic RNA, the fragment thereof or the amplicon thereof, or the EV-A71 protein or fragment thereof, wherein the one or more mutations are selected from mutations at positions corresponding to 5′ UTR nucleotide positions C580, A707, and C709 in an EV-A71 5′ UTR nucleic acid sequence and at residues corresponding to A280 and E145 in an EV-A71 VP1 protein sequence.

The invention is in the field of polynucleotides. The invention relates to a method for transcription using a nucleic acid construct that is characterized by the presence of a promoter that has been modified to disable the TATA box. This mutated promoter is followed by a second promoter. The invention further relates to that nucleic acid construct, to an expression vector or a cell comprising that construct, and to its use for improved transcription. Production of long RNA sequences was found to be improved by this construct.

The disclosure relates to methods and systems for the detection of low-quantity (e.g., 1×102 copies / μL) target nucleic acids (e.g., genomic RNA and / or genomic DNA).

The application discloses application of MG-132 in preparation of a drug for resisting nerve necrosis virus. Researches of the application show that MG-132 can significantly reduce the cytopathic effect caused by nerve necrosis virus infection, reduce the number of positive cells expressing RGNNV capsid protein, and also can significantly reduce the mRNA transcription level of a key gene of RGNNV, the protein expression level and the copy number of virus genomic RNA; and with the extension of RGNNV infection time, MG-132 can also significantly inhibit virus gene transcription, protein synthesis and genome replication, and reduce virus titer. Therefore, MG-132 treatment can significantly reduce the virulence of RGNNV to cells, has the efficacy of resisting nerve necrosis virus, and has low cytotoxicity and good safety. The application provides a new drug intervention strategy for prevention and treatment of nerve necrosis virus infection, and has important application value for prevention and control of NNV related diseases in aquaculture.

Modified antisense mucleic acid molecules ending with or without chain terminating bases targeting the HIV-1 viral genomic RNA 3′ LTR region, and uses thereof for inhibiting HIV-1 replication and infection, are disclosed. The antisense mucleic acid molecules more specifically target a sequence corresponding to about nucleotide 9628 to about nucleotide 9642 of HIV-1 clone pNL4-3.

The present invention relates to the adaptation and modification of Coxsackievirus B3 (CVB3) and their use or the use of their genomic RNA for the treatment of cancer, in particular for the treatment of gastrointestinal cancer, and furthermore particularly pancreatic and colorectal carcinomas.

The invention discloses application of CX-5461 in preparation of a medicine for resisting HEV (Hepatitis E Virus) infection, and belongs to the technical field of biological medicine. Bioinformatics prediction finds that a conservative G-quadruplex forming motif exists on HEV genome RNA, and in-vitro tests prove that CX-5461 can reduce the virus load and antigen level of infected cells; furthermore, meriones unguiculatus is taken as an animal model, CX-5461 intervention treatment is performed on gene type 1, type 3 and type 4 HEV infection models, and results show that the medicine can remarkably reduce the fecal virus detoxification amount of experimental animals, reduce the virus RNA load and antigen level of the liver and extrahepatic tissues (kidney and small intestine) and improve pathological injury of the liver. The invention provides a new therapeutic target and a safe and effective therapeutic drug for HEV infection.

A genome RNA extraction kit convenient to use comprises a kit body, first hinges, a kit cover, a built-in partition plate, an arc-shaped pressing rod, a double-torsion spring, a rotating cover plate, a rotating supporting plate and a magnetic sheet, the kit body is connected with the kit cover through the first hinges, the first hinges are distributed between the kit body and the kit cover, the built-in partition plate is matched with the kit body, and the arc-shaped pressing rod is connected with the rotating cover plate through the arc-shaped pressing rod. The rotating cover plates are inserted into the kit body and connected with the side surfaces of the kit body through second hinges, the rotating cover plates are symmetrically arranged in the kit body, the side surfaces of the rotating cover plates are provided with cover plate side plates, the symmetrical cover plate side plates are attached to each other, and the lower surfaces of the rotating cover plates are attached to the built-in partition plates. And the kit body and the kit cover are oppositely combined.

The application discloses a kind of based on single-domain antibody 9-4-1 immunomagnetic beads direct spread detection goat poxvirus kit and its application.The kit includes the single-domain antibody 9-4-1 immunomagnetic beads obtained by the single-domain antibody 9-4-1 shown in SEQ ID NO.1 goat poxvirus is coupled with magnetic bead by streptavidin-biotin.The single-domain antibody 9-4-1 protein purified by gel cutting is coupled with magnetic bead to obtain immunomagnetic beads, and after goat poxvirus is enriched, it can be directly amplified without extracting genomic RNA.The application overcomes the phenomenon that goat poxvirus is not easy to be found at virus replication peak period due to long time of forming sandwich, virus content is low when collecting disease material, detection rate is low, and a series of problems such as easy to miss detection;And it is time-consuming, costly and laborious to extract genomic DNA, and a series of problems such as environmental pollution during operation, and efficient, sensitive, specific, stable and practical, and the application provides an efficient technical means for detection of goat poxvirus disease.

The present application relates to a specific probe for detecting HCMV and a kit for isothermal amplification of HCMV, and belongs to the technical field of human cytomegalovirus detection.A specific probe for detecting HCMV, the probe comprises a sequence comprising a T7 promoter SEQ ID NO.21 and a sequence capable of recognizing a Cas13 protein SEQ ID NO.22.The present application uses the genomic RNA of the sample to be tested as a template, uses a specific primer probe set, performs isothermal amplification and CRISPR / Cas13 specific detection, and determines the results according to the fluorescence signal, so as to realize the qualitative detection of the infection state of human cytomegalovirus.Using RNA as a template, the latent state and active state of HCMV can be distinguished.

The invention relates to a genome RNA protective agent and a preparation method thereof, and belongs to the field of biology, the protective agent comprises 0.1%-0.3% of sucrose, 0.01%-0.02% of sodium chloride, 0.01%-0.05% of ammonium sulfate, 0.01%-0.2% of lactoalbumin hydrolysate, 0.01%-0.05% of disodium ethylene diamine tetraacetate, 0.01%-0.1% of triethanolamine and 0.01%-0.05% of procilin300, and a solvent is nuclease-free DEPC water. The genome RNA protective agent provided by the invention is used for protecting genome RNA, has colorless and transparent characters, has no influence on PCR amplification, and can stably preserve the genome RNA for 18 months or more at-20 DEG C or below.

The application discloses a kind of based on single-domain antibody 9-4-1 immunomagnetic bead direct spread detection small ruminant pestivirus kit and its application.The kit includes the single-domain antibody 9-4-1 immunomagnetic bead obtained by the single-domain antibody 9-4-1 shown in SEQ ID NO.1 small ruminant pestivirus through streptavidin-biotin and magnetic bead coupling.The single-domain antibody 9-4-1 protein purified by gel cutting is coupled with magnetic bead to obtain immunomagnetic bead, after small ruminant pestivirus is enriched by immunomagnetic bead, it can be directly amplified without extracting genomic RNA.The application overcomes the problems of low virus content, low detection rate, easy to miss detection, etc.;And a series of problems such as time-consuming, costly, laborious, environmental pollution during operation when extracting genomic RNA, by directly amplifying enrichment product, not only save time, save resources, but also efficient, sensitive, specific, stable, the application provides a kind of efficient technical means for small ruminant pestivirus antigen detection.